What is he best known for?
The fields of study he is best known for:
His primary areas of investigation include Molecular biology, Ubiquitin, Immunology, Endothelium and Internal medicine.
His Molecular biology research includes elements of Microphthalmia-associated transcription factor, Transcription factor, Ubiquitin-conjugating enzyme and Cell biology.
His study in Cell biology focuses on Myocyte in particular.
His study in Ubiquitin is interdisciplinary in nature, drawing from both Proteases, BCL2-related protein A1 and Northern blot.
His research in Endothelium intersects with topics in Endothelial stem cell, Cytokine, Cell adhesion molecule, Monocyte and Umbilical vein.
The concepts of his Internal medicine study are interwoven with issues in Endocrinology and Cardiology.
His most cited work include:
- Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells (1734 citations)
- Identification of the molecular basis of doxorubicin-induced cardiotoxicity (923 citations)
- Identification of the molecular basis of doxorubicin-induced cardiotoxicity (923 citations)
What are the main themes of his work throughout his whole career to date?
Edward T.H. Yeh focuses on Cell biology, Internal medicine, Molecular biology, SUMO protein and Biochemistry.
His Cell biology research focuses on subjects like Endothelial stem cell, which are linked to Endothelium and Cell adhesion molecule.
His biological study spans a wide range of topics, including Endocrinology, Oncology and Cardiology.
The Molecular biology study combines topics in areas such as Origin recognition complex, Eukaryotic DNA replication, Control of chromosome duplication, Histone and Gene silencing.
His work investigates the relationship between SUMO protein and topics such as Proteases that intersect with problems in Signal transduction.
His Heart failure research is multidisciplinary, incorporating perspectives in Cancer, Chemotherapy and Intensive care medicine.
He most often published in these fields:
- Cell biology (43.36%)
- Internal medicine (24.34%)
- Molecular biology (28.76%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (24.34%)
- Cardiotoxicity (15.93%)
- Cancer (15.49%)
In recent papers he was focusing on the following fields of study:
Edward T.H. Yeh mainly investigates Internal medicine, Cardiotoxicity, Cancer, Cell biology and Intensive care medicine.
Edward T.H. Yeh combines subjects such as Endocrinology, Isocitrate dehydrogenase and Cardiology with his study of Internal medicine.
His Cardiotoxicity study is concerned with Chemotherapy in general.
The Cancer study combines topics in areas such as Surgery, Heart failure, Oncology, MEDLINE and Immunology.
His Cell biology study incorporates themes from SUMO protein and Receptor.
As a part of the same scientific family, Edward T.H. Yeh mostly works in the field of Ubiquitin, focusing on Regulation of gene expression and, on occasion, Molecular biology.
Between 2013 and 2021, his most popular works were:
- Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities (317 citations)
- Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities (317 citations)
- Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. (139 citations)
In his most recent research, the most cited papers focused on:
His main research concerns Cardiotoxicity, Intensive care medicine, Internal medicine, Anthracycline and Cardiology.
His Intensive care medicine research incorporates themes from Cardiovascular Complication, Cardiomyopathy, Disease management and Cancer.
He has researched Cardiovascular Complication in several fields, including Targeted therapy, Pericardium, Radiation therapy and Atrial fibrillation.
His research in Cancer intersects with topics in Bioinformatics and Pathology.
His Internal medicine study is mostly concerned with Cardioprotection, Troponin I, Chemotherapy, Ejection fraction and Cardiac imaging.
His Cardiology research is multidisciplinary, relying on both Anthracycline induced cardiotoxicity, Secondary prevention, Doxorubicin and Molecular targets.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
